Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: A meta-analysis

Psychiatry Research

Volumn 207, Issue 1-2, 2013, Pages 1-12

  Hoen, Wendela P ^a   Lijmer, Jeroen G ^b   Duran, Marinus ^c   Wanders, Ronald J A ^c   Van Beveren, Nico J M ^d,e   De Haan, Lieuwe ^c  

^a JellinekMentrum   (Netherlands)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d Delta Psychiatrisch Centrum   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Fatty acids; Meta analysis; Polyunsaturated fatty acids (PUFA); Psychosis; Psychotic disorders

Indexed keywords

DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; NEUROLEPTIC AGENT; POLYUNSATURATED FATTY ACID;

ADULT; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFECT; ERYTHROCYTE; ERYTHROCYTE MEMBRANE; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; TREATMENT RESPONSE;

DATABASES, FACTUAL; ERYTHROCYTES; FATTY ACIDS, UNSATURATED; SIZOFIRAN;

EID: 84876876481     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.09.041     Document Type: Review

References (54)

1. Adams I.B., Martin B.R. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996, 91:1585-1614.
2. Akter K., Gallo D.A., Martin S.A., Myronyuk N., Roberts R.T., Stercula K., Raffa R.B. A review of the possible role of the essential fatty acids and fish oils in the aetiology, prevention or pharmacotherapy of schizophrenia. Journal of Clinical Pharmacy and Therapeutics 2011, 37:132-139.
3. Amminger G.P., Schafer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., Mackinnon A., McGorry P.D., Berger G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Archives of General Psychiatry 2010, 67:146-154.
4. Arvindakshan M., Ghate M., Ranjekar P.K., Evans D.R., Mahadik S.P. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophrenia Research 2003, 62:195-204.
5. Arvindakshan M., Sitasawad S., Debsikdar V., Ghate M., Evans D., Horrobin D.F., Bennett C., Ranjekar P.K., Mahadik S.P. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biological Psychiatry 2003, 53:56-64.
6. Assies J., Lieverse R., Vreken P., Wanders R.J., Dingemans P.M., Linszen D.H. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biological Psychiatry 2001, 49:510-522.
7. Bentsen H., Solberg D.K., Refsum H., Gran J.M., Bohmer T., Torjesen P.A., Halvorsen O., Lingjaerde O. Bimodal distribution of polyunsaturated fatty acids in schizophrenia suggests two endophenotypes of the disorder. Biological Psychiatry 2011, 70:97-105.
8. Clark, O., Djulbegovic, B., 2001. Forest plots in excel software (data sheet). Available at: . http://www.evidencias.com.
9. Connor C.M., Crawford B.C., Akbarian S. White matter neuron alterations in schizophrenia and related disorders. International Journal of Developmental Neuroscience 2011, 29:325-334.
10. DerSimonian R., Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986, 7:177-188.
11. Di X., Chan R.C., Gong Q.Y. White matter reduction in patients with schizophrenia as revealed by voxel-based morphometry: an activation likelihood estimation meta-analysis. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2009, 33:1390-1394.
12. Doris A.B., Wahle K., MacDonald A., Morris S., Coffey I., Muir W., Blackwood D. Red cell membrane fatty acids, cytosolic phospholipase-A2 and schizophrenia. Schizophrenia Research 1998, 31:185-196.
13. Evans D.R., Parikh V.V., Khan M.M., Coussons C., Buckley P.F., Mahadik S.P. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukotriens and Essential Fatty Acids 2003, 69:393-399.
14. Fukuzako H., Fukuzako T., Kodama S., Hashiguchi T., Takigawa M., Fujimoto T. Haloperidol improves membrane phospholipid abnormalities in temporal lobes of schizophrenic patients. Neuropsychopharmacology 1999, 21:542-549.
15. Felder C.C., Veluz J.S., Williams H.L., Briley E.M., Matsuda L.A. Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Molecular Pharmacology 1992, 42:838-845.
16. Fusar-Poli P., Berger G. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. Journal of Clinical Psychopharmacology 2012, 32:179-185.
17. Glen A.I., Glen E.M., Horrobin D.F., Vaddadi K.S., Spellman M., Morse-Fisher N., Ellis K., Skinner F.S. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophrenia Research 1994, 12:53-61.
18. Hamazaki K., Choi K.H., Kim H.Y. Phospholipid profile in the postmortem hippocampus of patients with schizophrenia and bipolar disorder: no changes in docosahexaenoic acid species. Journal of Psychiatric Research 2010, 44:688-693.
19. Hibbeln J.R., Makino K.K., Martin C.E., Dickerson F., Boronow J., Fenton W.S. Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder. Biological Psychiatry 2003, 53:431-441.
20. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. British Medical Journal 2003, 327:557-560.
21. Horrobin D.F., Glen A.I., Hudson C.J. Possible relevance of phospholipid abnormalities and genetic interactions in psychiatric disorders: the relationship between dyslexia and schizophrenia. Medical Hypotheses 1995, 45:605-613.
22. Horrobin D.F., Glen A.I., Vaddadi K. The membrane hypothesis of schizophrenia. Schizophrenia Research 1994, 13:195-207.
23. Horrobin D.F., Manku M.S., Hillman H., Iain A., Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biological Psychiatry 1991, 30:795-805.
24. Horrobin D.F. Schizophrenia: the illness that made us human. Medical Hypotheses 1998, 50:269-288.
25. Insel T.R. The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior. Neuron 2010, 65:768-779.
26. Joy C.B., Mumby-Croft R., Joy L.A. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database of Systematic Reviews 2006, 3:CD001257.
27. Kale A., Joshi S., Naphade N., Sapkale S., Raju M.S., Pillai A., Nasrallah H., Mahadik S.P. Opposite changes in predominantly docosahexaenoic acid (DHA) in cerebrospinal fluid and red blood cells from never-medicated first-episode psychotic patients. Schizophrenia Research 2008, 98:295-301.
28. Kemperman R.F., Veurink M., van der Wal T., Knegtering H., Bruggeman R., Fokkema M.R., Kema I.P., Korf J., Muskiet F.A. Low essential fatty acid and B-vitamin status in a subgroup of patients with schizophrenia and its response to dietary supplementation. Prostaglandins Leukotriens abd Essential Fatty Acids 2006, 74:75-85.
29. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophrenia Research 2002, 58:1-10.
30. Landén M., Davidsson P., Gottfries C.G., Månsson J.E., Blennow K. Reduction of the synaptophysin level but normal levels of glycerophospholipids in the gyrus cinguli in schizophrenia. Schizophrenia Research 2002, 55:83-88.
31. Mahadik S.P., Mukherjee S., Correnti E.E., Kelkar H.S., Wakade C.G., Costa R.M., Scheffer R. Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naive patients at the onset of psychosis. Schizophrenia Research 1994, 13:239-247.
32. McNamara R.K., Jandacek R., Rider T., Tso P., Hahn C., Richtand N.M., Stanford K.E. Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications. Schizophrenia Research 2007, 91:37-50.
33. Messamore E., Hoffman W.F., Yao J.K. Niacin sensitivity and the arachidonic acid pathway in schizophrenia. Schizophrenia Research 2010, 122:248-256.
34. Obi F.O., Nwanze E.A. Fatty acid profiles in mental disease. Part 1. Linolenate variations in schizophrenia. Journal of the Neurological Sciences 1979, 43:447-454.
35. Peet M., Laugharne J.D., Mellor J., Ramchand C.N. Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins Leukotriens and Essential Fatty Acids 1996, 55:71-75.
36. Peet M., Laugharne J., Rangarajan N., Horrobin D., Reynolds G. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. Journal of Psychiatric Research 1995, 29:227-232.
37. Peet M., Shah S., Selvam K., Ramchand C.N. Polyunsaturated fatty acid levels in red cell membranes of unmedicated schizophrenic patients. World Journal of Biological Psychiatry 2004, 5:92-99.
38. Peet M. Nutrition and schizophrenia: beyond omega-3 fatty acids. Prostaglandins, Leukotrienes and Essential Fatty Acids 2004, 70:417-422.
39. Perälä J., Suvisaari J., Saarni S.I., Kuoppasalmi K., Isometsä E., Pirkola S., Partonen T., Tuulio-Henriksson A., Hintikka J., Kieseppä T., Härkänen T., Koskinen S., Lönnqvist J. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Archives of General Psychiatry 2007, 64(1):19-28.
40. Peters B.D., Duran M., Vlieger E.J., Majoie C.B., den Heeten G.J., Linszen D.H., de Haan L. Polyunsaturated fatty acids and brain white matter anisotropy in recent-onset schizophrenia: a preliminary study. Prostaglandins Leukotrienes and Essential Fatty Acids 2009, 81:61-63.
41. Peters B.D., Machielsen M.W.J., Hoen W.P., Caan M.W.A., Malhotra A.K., Szeszko P.R., Duran M., Olabarriaga S.D., de Haan L. Polyunsaturated fatty acid concentration predicts myelin integrity in early-phase psychosis. Schizophrenia Bulletin 2012, 10.1093/schbul/sbs089.
42. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., Wagh U.V., Debsikdar V.B., Mahadik S.P. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Research 2003, 121:109-122.
43. Reddy R.D., Keshavan M.S., Yao J.K. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr Bulletin 2004, 30:901-911.
44. Sethom M.M., Fares S., Bouaziz N., Melki W., Jemaa R., Feki M., Hechmi Z., Kaabachi N. Polyunsaturated fatty acids deficits are associated with psychotic state and negative symptoms in patients with schizophrenia. Prostaglandins Leukotrienes and Essential Fatty Acids 2010, 83:131-136.
45. Strassnig M., Singh B.J., Ganguli R. Dietary fatty acid and antioxidant intake in community-dwelling patients suffering from schizophrenia. Schizophrenia Research 2005, 76:343-351.
46. Sumiyoshi T., Matsui M., Itoh H., Higuchi Y., Arai H., Takamiya C., Kurachi M. Essential polyunsaturated fatty acids and social cognition in schizophrenia. Psychiatry Research 2008, 157:87-93.
47. Vaddadi K.S., Courtney P., Gilleard C.J., Manku M.S., Horrobin D.F. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Research 1989, 27:313-323.
48. Vaddadi K.S., Gilleard C.J., Mindham R.H., Butler R. A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients. Psychopharmacology (Berl) 1986, 88:362-367.
49. Vaddadi K.S., Gilleard C.J., Soosai E., Polonowita A.K., Gibson R.A., Burrows G.D. Schizophrenia, tardive dyskinesia and essential fatty acids. Schizophrenia Research 1996, 20:287-294.
50. Wolf F.M. Meta-Analysis: Quantitative Methods for Research Synthesis 2011, Sage, Beverly Hills, CA.
51. Yao J.K., Reddy R.D. Membrane pathology in schizophrenia: implication for arachidonic acid signaling. ScientificWorld Journal 2002, 2:1922-1936.
52. Yao J., Stanley J.A., Reddy R.D., Keshavan M.S., Pettegrew J.W. Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites. Biological Psychiatry 2002, 52:823-830.
53. Yao J.K., van Kammen D.P., Welker J.A. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophrenia Research 1994, 13:217-226.
54. Yao J.K., Leonard S., Reddy R.D. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patiënts. Schizophrenia Research 2000, 42:7-17.